Corrigendum: Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination
Daniel Deme
Sandor Kovacs2 and - 1Department of Medical Oncology, Szent Lázár County Hospital, Salgótarján, Hungary
- 2Department of Economical and Financial Mathematics, University of Debrecen, Debrecen, Hungary
A Corrigendum on
Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination
by Deme D, Kovacs S and Telekes A (2022). Pathol. Oncol. Res. 28:1610004. doi: 10.3389/pore.2022.1610004
In the original article, there was a mistake in Table 2. In the last column of PLR the wrong patient number is 57. The correct patient number is 47. The corrected Table 2 appears below.
TABLE 2
TABLE 2. Comparison of the median OS based on the cut-off value for each significant biomarker.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: overall survival, advanced cancer, serum biomarkers, prognostic importance, CRP, albumin, PLR
Citation: Deme D, Kovacs S and Telekes A (2022) Corrigendum: Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination. Pathol. Oncol. Res. 28:1610517. doi: 10.3389/pore.2022.1610517
Received: 13 April 2022; Accepted: 27 April 2022;
Published: 18 May 2022.
Edited and reviewed by:
József Tímár, Semmelweis University, HungaryCopyright © 2022 Deme, Kovacs and Telekes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Daniel Deme, danieldeme_md@ymail.com
